FDA Panel Unanimously Rejects Regeneron's Arcalyst As Gout Treatment - Wall Street Journal

French Tribune

FDA Panel Unanimously Rejects Regeneron's Arcalyst As Gout Treatment Wall Street Journal Regeneron is seeking FDA approval for short-term use of a drug called Arcalyst to treat gout, a form of arthritis. Arcalyst, also known by its generic name rilonacept, is already on the market to treat a rare disease called Cryopyrin-Associated ... FDA Panel Nixes Gout DrugMedPage Today FDA Panel Votes Against Rilonacept For Gout Flare PreventionMedscape US FDA committtee voted against approval of Regeneron's Arcalyst for gout ...pharmabiz.com Sacramento Bee -The Pharma Letter all 59 news articles »

Arthritis Advisory Committee Unanimously Against Arcalyst for Gout - About - News & Issues

About - News & Issues

Arthritis Advisory Committee Unanimously Against Arcalyst for Gout About - News & Issues By Carol Eustice, About.com GuideMay 9, 2012 The Arthritis Advisory Committee voted 11-0 against recommending FDA approval of Arcalyst (rilonacept) for the prevention of gout flares in patients starting urate-lowering treatment. Regeneron's Arcalyst As Gout Treatment Rejected By FDA PanelThe Inquisitr FDA queries safety of Regeneron's Arcalyst for goutPharma Times UPDATE: Jefferies Lowers Regeneron Pharmaceuticals' PTBenzinga all 13 news articles »

The Gout Stages - EmpowHer

The Gout Stages EmpowHer By MC Kelby HERWriter May 9, 2012 - 2:05am Gout affects more than five million people in the United States. More than 5 percent of arthritis cases are diagnosed as gout, which is a very painful form of rheumatic arthritis. This very painful disease ...

FDA Review Has Safety Issues with Gout Drug - MedPage Today

FDA Review Has Safety Issues with Gout Drug MedPage Today The review was released in advance of Tuesday's FDA Arthritis Advisory Committee meeting, at which panelists will assess rilonacept's benefits and risks for the prevention of acute flares during the first 16 weeks of uric-acid lowering therapy. and more »